This content is PDF only. Please click on the PDF icon to access.
Available treatment for venous thromboembolic disease with thrombolytic and anticoagulant drugs is excellent. Current mortality from deep vein thrombosis and pulmonary emboli is approaching 5%. A further reduction clearly will require improved methods of prophylaxis. A means of significantly reducing potential catastrophic events associated with endogenous thrombus formation is outlined in this book. The merits of low-dose heparin with appropriate bedside monitoring is the central message in each of 13 chapters. The author intelligently points out the substantial frequency of hemorrhage associated with currently used regimens of low-dose heparin and correctly indicates the need for monitoring prophylactic heparin even in
Prevention of Venous Thrombosis and Pulmonary Embolism.. Ann Intern Med. ;95:401. doi: 10.7326/0003-4819-95-3-401_2
Download citation file:
Published: Ann Intern Med. 1981;95(3):401.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use